ReviewGene therapy2012
A novel lentivirus for quantitative assessment of gene knockdown in stem cell differentiation.
Review in Gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Activation of the Lactate Receptor GPR81 Ameliorates Senescence Hallmarks and Improves Muscle Function in Cellular and Progeroid Models of Aging.Aging cell · 2026Article
- Role of MLIP in burn-induced sepsis and insights into sepsis-associated cancer progression.Frontiers in immunology · 2025Article
- Dynamic reporters for probing real-time activation of human fibroblasts from single cells to populations.APL bioengineering · 2024Article
- Proline restores mitochondrial function and reverses aging hallmarks in senescent cells.Cell reports · 2024Article
- Inhibition of glutaminolysis restores mitochondrial function in senescent stem cells.Cell reports · 2022Article
- Endothelialization of arterial vascular grafts by circulating monocytes.Nature communications · 2020Article
- Restoring extracellular matrix synthesis in senescent stem cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Integrated Analysis of Methylome and Transcriptome Changes Reveals the Underlying Regulatory Signatures Driving Curly Wool Transformation in Chinese Zhongwei Goats.Frontiers in genetics · 2019Article
- Article
- Cadherin-11 is a novel regulator of extracellular matrix synthesis and tissue mechanics.Journal of cell science · 2016Article
- CDH2 and CDH11 act as regulators of stem cell fate decisions.Stem cell research · 2015Review
- Article
- Gene delivery strategies to promote spinal cord repair.Biomarker insights · 2015Review
- Transplantation of placenta-derived mesenchymal stem cell-induced neural stem cells to treat spinal cord injury.Neural regeneration research · 2014Article
- Construction and quantitative evaluation of a dual specific promoter system for monitoring the expression status of Stra8 and c-kit genes.Molecular biotechnology · 2014Article
- Lentiviral arrays for live-cell dynamic monitoring of gene and pathway activity during stem cell differentiation.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Plasmid-based shRNA lentiviral particle production for RNAi applications.Journal of biomolecular screening · 2014Article
- Cadherin-11 regulates both mesenchymal stem cell differentiation into smooth muscle cells and the development of contractile function in vivo.Journal of cell science · 2014Article
- Designing degradable hydrogels for orthogonal control of cell microenvironments.Chemical Society reviews · 2013Review
- Nanog reverses the effects of organismal aging on mesenchymal stem cell proliferation and myogenic differentiation potential.Stem cells (Dayton, Ohio) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Loss of gene function is a valuable tool for screening genes in cellular processes including stem cell differentiation differentiation. However, the criteria for evaluating gene knockdown are usually based on end-point analysis and real-time, dynamic information is lacking. To overcome these limitations, we engineered a shRNA encoding LentiViral Dual Promoter vector (shLVDP) that enabled real-time monitoring of mesenchymal stem (MSC) differentiation and simultaneous gene knockdown. In this vector, the activity of the alpha-smooth muscle actin (αSMA) promoter was measured by the expression of a destabilized green fluorescent protein, and was used as an indicator of myogenic differentiation; constitutive expression of discosoma red fluorescent protein was used to measure transduction efficiency and to normalize αSMA promoter activity; and shRNA was encoded by a doxycycline (Dox)-regulatable H1 promoter. Importantly, the normalized promoter activity was independent of lentivirus titer allowing quantitative assessment of gene knockdown. Using this vector, we evaluated 11 genes in the TGF-β1 or Rho signaling pathway on SMC maturation and on MSC differentiation along the myogenic lineage. As expected, knockdown of genes such as Smad2/3 or RhoA inhibited myogenic differentiation, while knocking down the myogenic differentiation inhibitor, Klf4, increased αSMA promoter activity significantly. Notably, some genes for example, Smad7 or KLF4 showed differential regulation of myogenic differentiation in MSC from different anatomic locations such as bone marrow and hair follicles. Finally, Dox-regulatable shRNA expression enabled temporal control of gene knockdown and provided dynamic information on the effect of different genes on myogenic phenotype. Our data suggests that shLVDP may be ideal for development of lentiviral microarrays to decipher gene regulatory networks of complex biological processes such as stem cell differentiation or reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.